BTIG Research reissued their hold rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued to investors on Tuesday.

Other research analysts also recently issued research reports about the stock. Barclays downgraded shares of Regeneron Pharmaceuticals from an equal weight rating to an underweight rating and reduced their price target for the stock from $450.00 to $395.00 in a research report on Friday, October 20th. Canaccord Genuity reiterated a buy rating on shares of Regeneron Pharmaceuticals in a research report on Monday, October 16th. Jefferies Group reiterated a hold rating and set a $421.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, February 2nd. Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the stock an equal weight rating in a research report on Friday, February 9th. Finally, JPMorgan Chase & Co. reiterated a hold rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 28th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $463.19.

Shares of Regeneron Pharmaceuticals (REGN) opened at $324.57 on Tuesday. Regeneron Pharmaceuticals has a 52 week low of $314.99 and a 52 week high of $543.55. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11. The company has a market cap of $34,890.00, a price-to-earnings ratio of 31.45, a PEG ratio of 1.27 and a beta of 1.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter in the previous year, the company earned $3.04 EPS. The firm’s revenue for the quarter was up 28.9% compared to the same quarter last year. sell-side analysts expect that Regeneron Pharmaceuticals will post 14.13 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 10.80% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Harding Loevner LP raised its holdings in Regeneron Pharmaceuticals by 589.2% during the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock worth $286,619,000 after purchasing an additional 3,131,966 shares during the last quarter. Polen Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Polen Capital Management LLC now owns 1,389,545 shares of the biopharmaceutical company’s stock worth $522,413,000 after purchasing an additional 15,931 shares during the last quarter. American Century Companies Inc. raised its holdings in Regeneron Pharmaceuticals by 2.3% during the 3rd quarter. American Century Companies Inc. now owns 917,554 shares of the biopharmaceutical company’s stock worth $410,257,000 after purchasing an additional 20,218 shares during the last quarter. Geode Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 880,481 shares of the biopharmaceutical company’s stock worth $330,385,000 after purchasing an additional 30,581 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Regeneron Pharmaceuticals by 516.8% during the 4th quarter. Renaissance Technologies LLC now owns 579,562 shares of the biopharmaceutical company’s stock worth $217,892,000 after purchasing an additional 485,600 shares during the last quarter. 65.89% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://theolympiareport.com/2018/02/14/regeneron-pharmaceuticals-regn-earns-hold-rating-from-btig-research.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.